Delays have real-world consequences.
Veterinarians, pet owners and livestock producers depend on safe and effective medicines to prevent, control and treat disease. When regulatory review is slow or unpredictable, access can be delayed and development costs can increase, which affects:
Animal Welfare
Timely access to medicines can prevent and alleviate disease and suffering.
Food safety
Healthy food-producing animals are an important foundation of a safe food supply.
Public health
Preventing and controlling animal disease can help reduce threats from diseases that move between animals and people.
Agriculture
Disease outbreaks can threaten livestock health and productivity, creating economic stress and putting pressure on the food supply.
Emerging threats don’t wait for regulatory timelines.
The response to New World Screwworm demonstrated that when circumstances demand urgency, FDA/CVM can use tools such as Emergency Use Authorization and Expanded Conditional Approval to move products through the system more quickly. That kind of flexibility does not need to be reserved for emergencies.
Modernization means getting the right answer more quickly without compromising safety.
A regulatory process that is faster, more predictable, and ready for innovation can maintain FDA standards for safety and effectiveness. Modernization includes:
Focusing on the science that matters.
Reviews can be designed around the scientific questions FDA needs to answer to make sound regulatory decisions, which can reduce time and complexity.
Creating pathways for emerging technologies.
Clear, science-based approaches for evaluating innovations are necessary for technologies that don’t fit neatly into legacy regulatory frameworks.
Making better use of data.
High-quality data and modern approaches can reduce unnecessary duplication while maintaining rigorous scientific standards.
Harmonizing where science allows.
It’s possible to work from common scientific standards with trusted regulatory partners to reduce unnecessary U.S.-specific duplication.
ADUFA VI
An opportunity to make modernization systematic
Congress has already demonstrated that drug-review modernization is possible: the 21st Century Cures Act modernized elements of the human drug approval process. Animal health deserves the same opportunity. ADUFA VI provides a vehicle to move modernization from isolated improvements to a more systematic approach. A more efficient, innovation-ready, harmonized regulatory system should ultimately help bring more safe and effective medicines to the animals that need them.






